{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:54:36Z","timestamp":1790776476924,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ajo.2026.07.039","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:58:34Z","timestamp":1785538714000},"page":"436-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy, Safety, and Durability of Gene Therapy for Inherited Retinal Diseases in the Pediatric Population: A Scoping Review"],"prefix":"10.1016","volume":"291","author":[{"given":"ALESSIA","family":"AMATO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GIANCARLO","family":"IAROSSI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7462-7725","authenticated-orcid":false,"given":"KIRK AJ","family":"STEPHENSON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajo.2026.07.039_bib0001","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.preteyeres.2010.03.004","article-title":"The molecular basis of human retinal and vitreoretinal diseases","volume":"29","author":"Berger","year":"2010","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"10.1016\/j.ajo.2026.07.039_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004015","article-title":"A comparison of the causes of blindness certifications in england and wales in working age adults (16-64 years), 1999-2000 with 2009-2010","volume":"4","author":"Liew","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.ajo.2026.07.039_bib0003","unstructured":"Daiger S.P., Sullivan L.S., Bowne S.J. RetNet: summaries of genes and loci causing retinal diseases. Retinal Information Network. Foundation Fighting Blindness; 2024. Accessed April 13, 2026. https:\/\/retnet.org\/."},{"issue":"1","key":"10.1016\/j.ajo.2026.07.039_bib0004","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s13023-021-02145-0","article-title":"Genetic testing and diagnosis of inherited retinal diseases","volume":"16","author":"Lam","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ajo.2026.07.039_bib0005","article-title":"Gene therapy in inherited retinal diseases: an update on current state of the art","volume":"8","author":"Amato","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.ajo.2026.07.039_bib0006","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40123-023-00862-2","article-title":"Gene therapy for inherited retinal diseases: from laboratory bench to patient bedside and beyond","volume":"13","author":"Brar","year":"2024","journal-title":"Ophthalmol Ther"},{"issue":"9","key":"10.1016\/j.ajo.2026.07.039_bib0007","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"issue":"35","key":"10.1016\/j.ajo.2026.07.039_bib0008","doi-asserted-by":"crossref","first-page":"12413","DOI":"10.1073\/pnas.0503460102","article-title":"RPE65 is the isomerohydrolase in the retinoid visual cycle","volume":"102","author":"Moiseyev","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.ajo.2026.07.039_bib0009","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ymthe.2020.11.029","article-title":"Clinical perspective: treating RPE65-associated retinal dystrophy","volume":"29","author":"Maguire","year":"2021","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ajo.2026.07.039_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","article-title":"Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years","volume":"130","author":"Jacobson","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"9701","key":"10.1016\/j.ajo.2026.07.039_bib0011","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ajo.2026.07.039_bib0012","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2026.07.039_bib0013","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1089\/hum.2018.014","article-title":"Results at 5 years after gene therapy for RPE65-deficient retinal dystrophy","volume":"29","author":"Pennesi","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"10097","key":"10.1016\/j.ajo.2026.07.039_bib0014","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ajo.2026.07.039_bib0015","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ophtha.2016.03.003","article-title":"Results at 2 years after gene therapy for RPE65-deficient leber congenital amaurosis and severe early-childhood-onset retinal dystrophy","volume":"123","author":"Weleber","year":"2016","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1016\/j.ajo.2026.07.039_bib0016","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber's congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ajo.2026.07.039_bib0017","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber's congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N Engl J Med"},{"issue":"10045","key":"10.1016\/j.ajo.2026.07.039_bib0018","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 Gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial","volume":"388","author":"Bennett","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ajo.2026.07.039_bib0019","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ophtha.2012.11.048","article-title":"Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2","volume":"120","author":"Testa","year":"2013","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2026.07.039_bib0020","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ymthe.2017.09.014","article-title":"Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 Leber congenital amaurosis","volume":"26","author":"Le Meur","year":"2018","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.ajo.2026.07.039_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2025.100876","article-title":"Efficacy and safety of voretigene neparvovec in RPE65-retinopathy: results of a phase III trial in Japan","volume":"5","author":"Fujinami","year":"2025","journal-title":"Ophthalmol Sci"},{"issue":"10","key":"10.1016\/j.ajo.2026.07.039_bib0022","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1172\/JCI69448","article-title":"Disruption of CEP290 microtubule\/membrane-binding domains causes retinal degeneration","volume":"123","author":"Drivas","year":"2013","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ajo.2026.07.039_bib0023","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/507318","article-title":"Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis","volume":"79","author":"den Hollander","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.ajo.2026.07.039_bib0024","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41591-018-0295-0","article-title":"Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect","volume":"25","author":"Cideciyan","year":"2019","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.ajo.2026.07.039_bib0025","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for CEP290-associated retinal degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ajo.2026.07.039_bib0026","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ajo.2026.07.039_bib0027","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ajo.2019.10.019","article-title":"GUCY2D-associated Leber congenital amaurosis: a retrospective natural history study in preparation for trials of novel therapies","volume":"210","author":"Bouzia","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.07.039_bib0028","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/ng1296-461","article-title":"Retinal-specific guanylate cyclase gene mutations in Leber's congenital amaurosis","volume":"14","author":"Perrault","year":"1996","journal-title":"Nat Genet"},{"issue":"10456","key":"10.1016\/j.ajo.2026.07.039_bib0029","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0140-6736(24)01447-8","article-title":"Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1\/2, multicentre, open-label, unilateral dose escalation study","volume":"404","author":"Yang","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ajo.2026.07.039_bib0030","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ophtha.2014.11.019","article-title":"Preserved outer retina in AIPL1 Leber's congenital amaurosis: implications for gene therapy","volume":"122","author":"Aboshiha","year":"2015","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2026.07.039_bib0031","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.1167\/iovs.03-0686","article-title":"The Expression of the Leber congenital amaurosis protein AIPL1 coincides with rod and cone photoreceptor development","volume":"44","author":"van der Spuy","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10479","key":"10.1016\/j.ajo.2026.07.039_bib0032","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0140-6736(24)02812-5","article-title":"Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study","volume":"405","author":"Michaelides","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ajo.2026.07.039_bib0033","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/humu.20461","article-title":"RPGR mutation analysis and disease: an update","volume":"28","author":"Shu","year":"2007","journal-title":"Hum Mutat"},{"issue":"10","key":"10.1016\/j.ajo.2026.07.039_bib0034","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1167\/iovs.17-23453","article-title":"The spectrum of structural and functional abnormalities in female carriers of pathogenic variants in the RPGR gene","volume":"59","author":"Talib","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2026.07.039_bib0035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ajo.2024.05.034","article-title":"Phase 1\/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) gene therapy: safety and efficacy in RPGR-associated X-linked retinitis pigmentosa","volume":"267","author":"Michaelides","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2026.07.039_bib0036","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ophtha.2024.02.023","article-title":"Assessment of visual function with cotoretigene toliparvovec in X-linked retinitis pigmentosa in the randomized XIRIUS phase 2\/3 study","volume":"131","author":"Lam","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.07.039_bib0037","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ajo.2024.11.021","article-title":"Subretinal Gene therapy drug AGTC-501 for XLRP phase 1\/2 multicenter study (HORIZON): 24-month safety and efficacy results","volume":"271","author":"Yang","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2026.07.039_bib0038","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1167\/iovs.16-19313","article-title":"Residual foveal cone structure in CNGB3-associated achromatopsia","volume":"57","author":"Langlo","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2026.07.039_bib0039","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ajo.2023.05.009","article-title":"First-in-Human gene therapy trial of AAV8-hCARp.HCNGB3 in adults and children with CNGB3-associated achromatopsia","volume":"253","author":"Michaelides","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.07.039_bib0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.preteyeres.2011.12.002","article-title":"X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms","volume":"31","author":"Molday","year":"2012","journal-title":"Prog Retin Eye Res"},{"issue":"12","key":"10.1016\/j.ajo.2026.07.039_bib0041","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.oret.2022.06.013","article-title":"Intravitreal delivery of rAAV2tYF-CB-hRS1 vector for gene augmentation therapy in patients with X-linked retinoschisis: 1-year clinical results","volume":"6","author":"Pennesi","year":"2022","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"10.1016\/j.ajo.2026.07.039_bib0042","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00439-016-1637-y","article-title":"Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial","volume":"135","author":"Ghazi","year":"2016","journal-title":"Hum Genet"},{"key":"10.1016\/j.ajo.2026.07.039_bib0043","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.2147\/JMDH.S539699","article-title":"Clinical research for inherited retinal disease related pediatric blindness: a preliminary descriptive analysis based on clinicaltrials.gov","volume":"18","author":"Ashour","year":"2025","journal-title":"J Multidiscip Healthc"},{"issue":"8S1","key":"10.1016\/j.ajo.2026.07.039_bib0044","doi-asserted-by":"crossref","first-page":"8S41","DOI":"10.1016\/S0929-693X(23)00226-9","article-title":"Update on gene therapies in pediatric ophthalmology","volume":"30","author":"Bremond-Gignac","year":"2023","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.ajo.2026.07.039_bib0045","article-title":"Gene therapies in pediatric ophthalmology","volume":"3","author":"Daruich","year":"2023","journal-title":"Front Ophthalmol (Lausanne)"},{"issue":"5","key":"10.1016\/j.ajo.2026.07.039_bib0046","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/IAE.0000000000003133","article-title":"Leber congenital amaurosis due to CEP290 mutations-severe vision impairment with a high unmet medical need: a review","volume":"41","author":"Leroy","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2026.07.039_bib0047","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ajo.2024.06.013","article-title":"Clinical and molecular characterization of AIPL1-associated Leber congenital amaurosis\/early-onset severe retinal dystrophy","volume":"266","author":"Zhang","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.07.039_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000003920","article-title":"A systematic literature review of disease progression reported in rpgr -associated X-linked retinitis pigmentosa","volume":"44","author":"Lam","year":"2024","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2026.07.039_bib0049","doi-asserted-by":"crossref","DOI":"10.3390\/biom14010122","article-title":"Real-world safety and effectiveness of voretigene neparvovec: results up to 2 years from the prospective, registry-based PERCEIVE study","volume":"14","author":"Fischer","year":"2024","journal-title":"Biomolecules"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:55:29Z","timestamp":1790772929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426004113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":49,"alternative-id":["S0002939426004113"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.07.039","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, Safety, and Durability of Gene Therapy for Inherited Retinal Diseases in the Pediatric Population: A Scoping Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.07.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}